Discovery
Pre-clinical
Phase 1
Phase 2

A Phase 1b trial is ongoing

Overview

Our technology for generating and identifying functional human antibodies may also be applied to disease areas outside of cancer. Examples include, but are not limited to, autoimmune and infectious disease targets.

Infectious disease agents are particularly attractive for our antibody discovery platform as it allows us to tap into an ongoing or a memory immune response in human patients. Isolation of B-cells from infectious disease patients enables us to identify those antibodies that are responsible for neutralizing the disease agent and hence are aiding in patient recovery. We have extensive experience in this area and have identified large repertoires of antibodies against various viruses and bacteria.

Target
S. aureus
Trial
Phase 1b ongoing
Patients
A randomized, double-blind, placebo-controlled, multiple-ascending dose study enrolling up to 24 patients

Clinical development of Sym009

This trial was initiated in July 2017 and is currently ongoing. Sym009 was originally discovered by isolating antibodies from individuals exposed to S.aureus using our patented Symplex® technology.

Publication

Novel antibody–antibiotic conjugate eliminates intracellular S. aureus

Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, Vandlen R, DePalatis L, Raab H, Hazenbos WL, Morisaki JH, Kim J, Park S, Darwish M, Lee BC, Hernandez H, Loyet KM, Lupardus P, Fong R, Yan D, Chalouni C, Luis E, Khalfin Y, Plise E, Cheong J, Lyssikatos JP, Strandh M, Koefoed K, Andersen PS, Flygare JA, Wah Tan M, Brown EJ, Mariathasan S.
Nature 527, 323–328 (2015)
Read more about our strategic partnerships